Radio and PodcastRadio and PodcastLive Radio & Podcasts
Gedatolisib et al artwork
Science & Medicine

Gedatolisib et al

OncoPharm by OncoPharmPod

Jul 23, 202600:18:16Science & Medicine

This week's pod covers some brief updates comparing the timelines of the FDA approvals for daraxonrasib vs. enfortuamb vedodin + pembrolizumab, before devoting the rest of the time to the new approval of gedatolisib, a P...

Related Episodes

Continue listening to more episodes from OncoPharm.

Lirafugratinib + LITESPARK011

Oct 1, 2026 - 00:15:34

This week's pod offers a brief review of FGFR inhibitors for cholangiocarcinoma in repsonse to the FDA ap...

PI3K Pathway Hyperglycemia

Sep 24, 2026 - 00:10:07

Drugs that inhibit signaling via the PI3K pathway (e.g. alpelisib, capivasertib) can cause hyperglycemia....

Paradigm and Daraxonrasib in NSCLC

Sep 3, 2026 - 00:14:31

PARADIGM is finally published, so we have more details from this study presented at ASH about HMA/Ven vs....

Iberdomide

Aug 20, 2026 - 00:15:37

CELMoDs are here, but are they here to stay? CELMoD/IMiD review article: Download the Oncology Learning C...